

**ATTORNEY'S DOCKET NUMBER 2003028-0048  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: Stuart L. Schreiber *et al.*

Application No.: 09/834,424

Filed: April 13, 2001

For: METHOD AND MATERIALS INVOLVING  
DIMERIZATION-MEDIATED  
REGULATION OF BIOLOGICAL EVENTS

Confirmation No.: 5917

Art Unit: 1636

Examiner: Nancy T. Vogel

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits after the filing of a request for continued examination under 37 CFR 1.114 (37 CFR 1.97(b)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2). This Information Disclosure Statement includes letters that were filed in an opposition to a European counterpart of one of the priority applications for the subject application. That European case, EP0787207, now stands revoked, with an appeal pending. Some of these letters were filed in French (see C15, C16, and C38). Applicants will gladly obtain English translations of these documents if the Examiner feels they would help her examine the present application. In this context, Applicants

note that C17, and C30-C33 are English documents from the same opposition (as filed by Applicants and by the European Patent Office) and that C37 is an English translation of document C15. Applicants also note that B2 is in French. The Abstract of B2 is in English and Applicants will gladly obtain an English translation of other portions of B2 if the Examiner feels this would help her examine the present application.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Applicants believe that no fees are due with this submission. The Director is hereby authorized to charge any fees that should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-1721, under Order No. 2003028-0048.

Dated: March 2, 2009

Respectfully submitted,

Electronic signature: /Charles E. Lyon/  
Charles E. Lyon, D.Phil., J.D.

Registration No.: 56,630  
Attorney for Applicant

CHOATE, HALL & STEWART  
2 International Place  
Boston, Massachusetts 02110

clyon@choate.com  
Tel. (617) 248-4793  
FAX (617) 502-5002